You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Next-Generation Therapeutics for IBD
|
|---|---|
| Published in |
Current Gastroenterology Reports, June 2015
|
| DOI | 10.1007/s11894-015-0444-2 |
| Pubmed ID | |
| Authors |
Mark Löwenberg, Geert D’Haens |
| Abstract |
Various novel drugs have recently been evaluated in clinical trials showing promising effects in patients with inflammatory bowel disease (IBD). Here, we summarize the recent literature in the area of emerging therapies in the field of IBD, with specific focus on anti-integrin antibodies, such as vedolizumab (anti-α4β7) and etrolizumab (anti-rhuMAb β7), and the Janus kinase (JAK) inhibitor tofacitinib. Moreover, we will discuss efficacy and safety data of golimumab (a new subcutaneous anti-tumor necrosis factor (TNF) antibody), Avaxia (an orally delivered anti-TNF antibody), and Budesonide MMX; all have been developed for the treatment of ulcerative colitis. Other therapeuticals that might find their way to the market the coming years include the anti-mucosal vascular addressin cell adhesion molecule (MAdCAM) PF-00547659, small molecules (including laquinimod and the CCR9 antagonist Vercirnon), as well as an orally active SMAD7 antisense oligonucleotide that showed clinical benefit in Crohn's disease patients. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 130 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 2% |
| Netherlands | 1 | <1% |
| Italy | 1 | <1% |
| Argentina | 1 | <1% |
| Unknown | 125 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 23 | 18% |
| Student > Master | 16 | 12% |
| Student > Bachelor | 15 | 12% |
| Student > Ph. D. Student | 14 | 11% |
| Other | 13 | 10% |
| Other | 28 | 22% |
| Unknown | 21 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 49 | 38% |
| Biochemistry, Genetics and Molecular Biology | 15 | 12% |
| Agricultural and Biological Sciences | 12 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 7% |
| Immunology and Microbiology | 9 | 7% |
| Other | 9 | 7% |
| Unknown | 27 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2023.
All research outputs
#5,264,158
of 25,457,858 outputs
Outputs from Current Gastroenterology Reports
#3
of 3 outputs
Outputs of similar age
#61,914
of 282,240 outputs
Outputs of similar age from Current Gastroenterology Reports
#2
of 3 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.9. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 282,240 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.